Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
•
Medical Oncology
•
Breast Cancer, Metastatic
Are you comfortable combining palliative radiotherapy with capivasertib/fulvestrant?
Any pitfalls to be aware of?
Answer from: Medical Oncologist at Community Practice
Yes. Follow CBC
Sign in or Register to read more
22945
Related Questions
What are your top takeaways in Breast Cancer from ASTRO 2024?
What are your top takeaways in Medical Oncology from SABCS 2024?
What are your top takeaways in Breast Cancer from ESMO 2024?
In patients with HER-2 positive breast cancer on pertuzumab/trastuzumab with newly developed asymptomatic brain metastases only, do you wait 3 weeks after administration of the targeted therapy to deliver SRS?
What is the current paradigm for breast cancer diagnosed with isolated metastases prior to initial treatment?
How would you treat a patient with HER2 positive CNS only progression on fam-trastuzumab which had previously progressed on tucatinib/capecitabine/trastuzumab, and has failed both SRS and WBRT?
What are your top takeaways in Radiation Oncology from SABCS 2024?
In a patient with BRCA2 mutation and contralateral axillary recurrence of ER+ IDC with an ESR1 CCDC170 fusion on NGS testing, would you use standard adjuvant AI therapy or consider adjuvant SERD therapy (fulvestrant/elacestrant)?
In patients with advanced HR+, HER2- breast cancer who have progressed on first-line CDK 4/6i and ET and found to have ESR1 mutation, are you offering combination of abemaciclib and elacestrant in the 2nd line or SERD monotherapy?
What is your experience and treatment efficacy of tucatinib if used after enhertu in metastatic breast cancer?